Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Mar 2001
Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.
Women and their clinicians are increasingly encouraged to use risk estimates derived from statistical models, primarily that of Gail et al., to aid decision making regarding potential prevention options for breast cancer, including chemoprevention with tamoxifen. ⋯ The Gail et al. model 2 fit well in this sample in terms of predicting numbers of breast cancer cases in specific risk factor strata but had modest discriminatory accuracy at the individual level. This finding has implications for use of the model in clinical counseling of individual women.
-
J. Natl. Cancer Inst. · Jan 2001
Meta AnalysisPrognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Uncertainty about prognosis and treatment of axillary lymph node-negative patients with estrogen receptor (ER)-negative or ER-positive invasive breast tumors of 1 cm or less prompted the analysis of data from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. ⋯ Chemotherapy and/or tamoxifen should be considered for the treatment of women with ER-negative or ER-positive tumors of 1 cm or less and negative axillary lymph nodes.
-
J. Natl. Cancer Inst. · Jan 2001
Randomized Controlled Trial Multicenter Study Clinical TrialGranulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
Granulocyte colony-stimulating factors (G-CSFs) have been shown to help prevent febrile neutropenia in certain subgroups of cancer patients undergoing chemotherapy, but their role in treating febrile neutropenia is controversial. The purpose of our study was to evaluate-in a prospective multicenter randomized clinical trial-the efficacy of adding G-CSF to broad-spectrum antibiotic treatment of patients with solid tumors and high-risk febrile neutropenia. ⋯ Adding G-CSF to antibiotic therapy shortens the duration of neutropenia, reduces the duration of antibiotic therapy and hospitalization, and decreases hospital costs in patients with high-risk febrile neutropenia.